Valence-Logo
Beliebt
Anmelden
Loading data for ELDN — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Eledon Pharmaceuticals In...

NasdaqCM: ELDN · Echtzeitkurs · USD
3.62
+0.04 (1.12%)
Zum Schluss: Aug 18, 2026, 8:00 PM
3.64
+0.55%
Vorbörslich: 7:35 AM

Eledon Pharmaceuticals Inc. (ELDN) Stock Price, Analysis & Data

1.12%

Keine Daten verfügbar

Geld2.61
Marktkapitalisierung294.17 Mio
Umsatz (TTM)n/a
Nettogewinn (TTM)-98.56 Mio
Beta0.96
EPS (ttm)-0.9
KGV (TTM)n/a
Forward-KGV-4.7
KBV (TTM)2.74
KUV (TTM)n/a
Earnings DateNov 13, 2026
Brief4.51
Volumen587,695
Ø Vol. (20D)1,273,829
Eröffnung3.54
Vortagesschluss3.58
Tagesspanne3.54 - 3.68
52-Wk Range1.35 - 4.60
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic po...

[Mehr lesen]
Branche Biotechnology
Sektor Healthcare
IPO Datum Sep 17, 2014
Mitarbeiter 33
Börse NasdaqCM
Tickersymbol ELDN
Website https://eledon.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Eledon Pharmaceuticals 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -45.62 Mio, ein Anstieg von 26.07 %.

Finanzberichte

Gewinnüberraschung

Eledon Pharmaceuticals hat die Quartalszahlen am Aug 13, 2026 veröffentlicht:
  • Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.
  • EPS von -0.27 verfehlt die Erwartungen um -0.12, mit -107.69% Rückgang im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Eledon Pharmaceuticals Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 13, 2026, während der Handelszeiten.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 2 Monaten · Zacks

    Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

    Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

    news image

    vor 2 Monaten · Insider Monkey

    Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart

    While Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has gained 125.83% year-to-date, analysts continue to see 134.60% upside, helping it secure a spot on our list of the hot biotech stocks under $5 to bu...

    news image

    vor 2 Monaten · Zacks

    Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?

    Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

    news image

    vor 3 Monaten · Benzinga

    EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

    NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes ...

    news image

    vor 4 Monaten · Insider Monkey

    Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money

    Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double...

    Seite 1 von 2